News More Safety Data Needed for Intravitreal Anti-VEGF Agents by Medscape • 2014/08/05 • 0 Comments Intravitreal use of bevacizumab and ranibizumab does not appear to cause major cardiovascular events or non-ocular bleeding in patients with eye disease, according to a meta-analysis from France. Reuters Health Information